Bicara Therapeutics prices $150 million stock offering at $16
#Bicara Therapeutics #Stock Offering #Ficerafusp Alfa #Biopharmaceutical #NASDAQ:BCAX #Cancer Treatment #Clinical Trials #FDA Approval
📌 Key Takeaways
- Bicara Therapeutics priced a $150 million stock offering at $16 per share
- The offering includes 7,175,000 common shares and 2,200,000 pre-funded warrants
- Proceeds will support regulatory filing and commercial launch of ficerafusp alfa
- Funds will accelerate development and manufacturing of the drug candidate
- Joint book-running managers include Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel
📖 Full Retelling
Bicara Therapeutics Inc. (NASDAQ:BCAX) priced an underwritten public offering of 7,175,000 shares of common stock at $16.00 per share in Boston on Monday, February 24, 2026, to raise approximately $150 million for advancing its lead drug candidate ficerafusp alfa through regulatory approval and commercialization. The clinical-stage biopharmaceutical company also offered pre-funded warrants to purchase 2,200,000 shares at $15.9999 per warrant to certain investors, with gross proceeds expected to reach approximately $150 million before deducting underwriting discounts and commissions. The offering is scheduled to close on February 26, 2026, subject to customary closing conditions, and Bicara has granted underwriters a 30-day option to purchase up to 1,406,250 additional shares at the public offering price. Bicara plans to allocate the net proceeds to invest in medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa in the United States, if approved, with additional funds supporting accelerated development of the drug in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule.
🏷️ Themes
Biopharmaceutical Financing, Drug Development, Stock Offering, Cancer Treatment
📚 Related People & Topics
Biopharmaceutical
Drug made from biological source
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, alle...
Entity Intersection Graph
Connections for Biopharmaceutical:
🌐
Insider trading
2 shared
🌐
Cystic fibrosis
1 shared
🌐
Clinical trial
1 shared
🏢
RBC Capital Markets
1 shared
🌐
Chief strategy officer
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Bicara Therapeutics prices $150 million stock offering at $16 By Investing.com Company News Published 02/24/2026, 11:21 PM Bicara Therapeutics prices $150 million stock offering at $16 0 BCAX -0.98% BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX) priced an underwritten public offering of 7,175,000 shares of common stock at $16.00 per share, the company announced Monday. The clinical-stage biopharmaceutical company is also offering pre-funded warrants to purchase 2,200,000 shares at $15.9999 per warrant to certain investors. The gross proceeds are expected to reach approximately $150 million before deducting underwriting discounts and commissions, according to a press release statement. The offering is expected to close on February 26, 2026, subject to customary closing conditions. Bicara has granted underwriters a 30-day option to purchase up to 1,406,250 additional shares at the public offering price. The company plans to use the net proceeds to invest in medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa, if approved, in the United States. Additional funds will support accelerated development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule. The proceeds will also fund manufacturing costs for ongoing and anticipated drug development efforts, early signal-finding for future indication expansion, and general corporate purposes. Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel are serving as joint book-running managers for the offering. The sec...
Read full article at source